NASDAQ:APLS - Apellis Pharmaceuticals Stock Price, News & Analysis

$28.33
-1.59 (-5.31 %)
(As of 08/23/2019 04:00 PM ET)
Today's Range
$28.25
Now: $28.33
$29.90
50-Day Range
$25.44
MA: $27.63
$30.00
52-Week Range
$11.45
Now: $28.33
$30.25
Volume242,100 shs
Average Volume414,817 shs
Market Capitalization$1.80 billion
P/E RatioN/A
Dividend YieldN/A
Beta0.75
Apellis Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, focuses on the development of therapeutic compounds through the inhibition of the complement system for autoimmune and inflammatory diseases. Its lead product candidate is APL-2 that is in Phase III clinical trials for the treatment of geographic atrophy in age-related macular degeneration and paroxysmal nocturnal hemoglobinuria diseases; and in Phase II clinical trials for the treatment of cold agglutinin and warm antibody autoimmune hemolytic anemia diseases, as well as in Phase II clinical trials to treat four types of glomerular diseases, such as C3 glomerulopathy, IgA nephropathy, primary membranous nephropathy, and lupus nephritis. Read More…

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:APLS
CUSIPN/A
Phone502-241-4114

Debt

Price-To-Earnings

Sales & Book Value

Annual SalesN/A
Book Value$2.50 per share

Profitability

Net Income$-127,500,000.00

Miscellaneous

Employees87
Market Cap$1.80 billion
Next Earnings Date11/12/2019 (Estimated)
OptionableNot Optionable

Receive APLS News and Ratings via Email

Sign-up to receive the latest news and ratings for APLS and its competitors with MarketBeat's FREE daily newsletter.


Apellis Pharmaceuticals (NASDAQ:APLS) Frequently Asked Questions

What is Apellis Pharmaceuticals' stock symbol?

Apellis Pharmaceuticals trades on the NASDAQ under the ticker symbol "APLS."

How were Apellis Pharmaceuticals' earnings last quarter?

Apellis Pharmaceuticals Inc (NASDAQ:APLS) released its quarterly earnings results on Wednesday, July, 31st. The company reported ($0.98) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.80) by $0.18. View Apellis Pharmaceuticals' Earnings History.

When is Apellis Pharmaceuticals' next earnings date?

Apellis Pharmaceuticals is scheduled to release their next quarterly earnings announcement on Tuesday, November 12th 2019. View Earnings Estimates for Apellis Pharmaceuticals.

What price target have analysts set for APLS?

7 Wall Street analysts have issued 1 year target prices for Apellis Pharmaceuticals' shares. Their forecasts range from $40.00 to $52.00. On average, they expect Apellis Pharmaceuticals' share price to reach $45.1429 in the next year. This suggests a possible upside of 59.3% from the stock's current price. View Analyst Price Targets for Apellis Pharmaceuticals.

What is the consensus analysts' recommendation for Apellis Pharmaceuticals?

7 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Apellis Pharmaceuticals in the last year. There are currently 7 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Apellis Pharmaceuticals.

What are Wall Street analysts saying about Apellis Pharmaceuticals stock?

Here are some recent quotes from research analysts about Apellis Pharmaceuticals stock:
  • 1. According to Zacks Investment Research, "Apellis Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. It focused on the development of novel therapeutic compounds to treat disease through the inhibition of the complement system, which is an integral component of the immune system, at the level of C3, the central protein in the complement cascade. Apellis Pharmaceuticals, Inc. is based in CRESTWOOD, United States. " (7/16/2019)
  • 2. Cantor Fitzgerald analysts commented, ": We are reiterating our OW rating on Apellis and lowering our 12-month price target to $52 from $57. This morning, Apellis issued a press release highlighting financial and corporate updates for the period ended on 3/31. Our decrease in price target is based off an increased share count, due to the recent March 2019 financing, and an increase to R&D and SG&A projections. With Phase 3 PEGASUS (PNH) enrollment expected to complete by the end of 2Q19, we believe APLS shares represent a strong buying opportunity, ahead of a potential 4Q19 data readout. Below we revisit our thoughts on APL-2 and its potential to be a disruptive addition to the PNH market." (5/8/2019)

Has Apellis Pharmaceuticals been receiving favorable news coverage?

Media headlines about APLS stock have been trending positive recently, according to InfoTrie Sentiment Analysis. InfoTrie identifies negative and positive press coverage by monitoring more than six thousand blog and news sources. The firm ranks coverage of public companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Apellis Pharmaceuticals earned a coverage optimism score of 2.5 on InfoTrie's scale. They also assigned news articles about the company a news buzz of 6.0 out of 10, indicating that recent press coverage is somewhat likely to have an impact on the company's share price in the near future. View News Stories for Apellis Pharmaceuticals.

Are investors shorting Apellis Pharmaceuticals?

Apellis Pharmaceuticals saw a decline in short interest in July. As of July 31st, there was short interest totalling 2,398,100 shares, a decline of 6.6% from the June 30th total of 2,567,900 shares. Based on an average trading volume of 396,300 shares, the short-interest ratio is presently 6.1 days. Currently, 7.6% of the shares of the company are short sold. View Apellis Pharmaceuticals' Current Options Chain.

Who are some of Apellis Pharmaceuticals' key competitors?

What other stocks do shareholders of Apellis Pharmaceuticals own?

Who are Apellis Pharmaceuticals' key executives?

Apellis Pharmaceuticals' management team includes the folowing people:
  • Dr. Cedric Francois, Co-Founder, Pres, CEO & Director (Age 47)
  • Dr. Pascal Deschatelets, Co-Founder & COO (Age 49)
  • Mr. Timothy E. Sullivan, Chief Financial Officer (Age 48)
  • Dr. Federico Grossi M.D., Ph.D., Co-Founder and Exec. VP of Clinical Devel. & Medical Affairs (Age 45)
  • Mr. Ahmad Sadr, VP of Technical Operations

When did Apellis Pharmaceuticals IPO?

(APLS) raised $150 million in an initial public offering on Thursday, November 9th 2017. The company issued 10,700,000 shares at $13.00-$15.00 per share. Citigroup, J.P. Morgan and Evercore ISI acted as the underwriters for the IPO.

Who are Apellis Pharmaceuticals' major shareholders?

Apellis Pharmaceuticals' stock is owned by a variety of of retail and institutional investors. Top institutional investors include BlackRock Inc. (7.07%), Cormorant Asset Management LP (4.66%), Vanguard Group Inc. (3.22%), Victory Capital Management Inc. (2.61%), Jennison Associates LLC (1.45%) and Jennison Associates LLC (1.45%). Company insiders that own Apellis Pharmaceuticals stock include Cedric Francois, David O Watson, Global Strategic Fund I Venbio, Lukas Scheibler and Morningside Venture Investment. View Institutional Ownership Trends for Apellis Pharmaceuticals.

Which major investors are selling Apellis Pharmaceuticals stock?

APLS stock was sold by a variety of institutional investors in the last quarter, including Morgan Stanley, Cormorant Asset Management LP, Westfield Capital Management Co. LP, Citadel Advisors LLC, Fosun International Ltd, Victory Capital Management Inc., Prudential Financial Inc. and Royal Bank of Canada. Company insiders that have sold Apellis Pharmaceuticals company stock in the last year include Cedric Francois and David O Watson. View Insider Buying and Selling for Apellis Pharmaceuticals.

Which major investors are buying Apellis Pharmaceuticals stock?

APLS stock was bought by a variety of institutional investors in the last quarter, including BlackRock Inc., Jennison Associates LLC, Jennison Associates LLC, Nuveen Asset Management LLC, DekaBank Deutsche Girozentrale, Point72 Asset Management L.P., Pictet Asset Management Ltd. and Pictet Asset Management Ltd.. Company insiders that have bought Apellis Pharmaceuticals stock in the last two years include Global Strategic Fund I Venbio, Lukas Scheibler and Morningside Venture Investment. View Insider Buying and Selling for Apellis Pharmaceuticals.

How do I buy shares of Apellis Pharmaceuticals?

Shares of APLS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Apellis Pharmaceuticals' stock price today?

One share of APLS stock can currently be purchased for approximately $28.33.

How big of a company is Apellis Pharmaceuticals?

Apellis Pharmaceuticals has a market capitalization of $1.80 billion. The company earns $-127,500,000.00 in net income (profit) each year or ($2.34) on an earnings per share basis. Apellis Pharmaceuticals employs 87 workers across the globe.View Additional Information About Apellis Pharmaceuticals.

What is Apellis Pharmaceuticals' official website?

The official website for Apellis Pharmaceuticals is http://www.apellis.com/.

How can I contact Apellis Pharmaceuticals?

Apellis Pharmaceuticals' mailing address is 6400 WESTWIND WAY SUITE A, CRESTWOOD KY, 40014. The company can be reached via phone at 502-241-4114 or via email at [email protected]


MarketBeat Community Rating for Apellis Pharmaceuticals (NASDAQ APLS)

Community Ranking:  2.8 out of 5 (star star)
Outperform Votes:  151 (Vote Outperform)
Underperform Votes:  116 (Vote Underperform)
Total Votes:  267
MarketBeat's community ratings are surveys of what our community members think about Apellis Pharmaceuticals and other stocks. Vote "Outperform" if you believe APLS will outperform the S&P 500 over the long term. Vote "Underperform" if you believe APLS will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 8/24/2019 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel